The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.

[1]  M. Slovak,et al.  Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. , 2007, Leukemia research.

[2]  A. Órfão,et al.  KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. , 2006, Blood.

[3]  C. Bloomfield,et al.  Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  W. Hiddemann,et al.  1 KIT-D 816 mutations in AML 1-ETO positive AML are associated with impaired event-free and overall survival , 2005 .

[5]  A. Barrett,et al.  A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis , 2006, Bone Marrow Transplantation.

[6]  T. Brümmendorf,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2004, Blood.

[7]  C. Fonatsch,et al.  Myelomastocytic Leukemia: Evidence for the Origin of Mast Cells from the Leukemic Clone and Eradication by Allogeneic Stem Cell Transplantation , 2005, Clinical Cancer Research.

[8]  A. Pardanani.  Systemic Mastocytosis: Bone Marrow Pathology, Classification, and Current Therapies , 2005, Acta Haematologica.

[9]  Guoqiang Chen,et al.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Sotlar,et al.  Mastocytosis: Pathology, genetics, and current options for therapy , 2005, Leukemia & lymphoma.

[11]  C. Waller,et al.  Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation , 2004, Bone Marrow Transplantation.

[12]  H. Bernd,et al.  Acute myeloid leukaemia with t(8;21) associated with “occult” mastocytosis. Report of an unusual case and review of the literature , 2004, Journal of Clinical Pathology.

[13]  H. Cavé,et al.  Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.

[14]  W. Su,et al.  Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation , 2003, Bone Marrow Transplantation.

[15]  S. Ogawa,et al.  [Establishment of a quantitative method for detecting mixed chimerism using fluorescence-based PCR amplification of short tandem repeat markers after allogeneic hematopoietic stem cell transplantation in a Japanese population]. , 2002, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[16]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[17]  E. Macintyre,et al.  Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease , 1999, Leukemia.

[18]  B. Foster,et al.  Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). , 1999, Blood.

[19]  M. Florek,et al.  Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection , 1999, Bone Marrow Transplantation.